Education
About Us
Working with TipRanks
Follow Us
PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
PRCT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$47.04 - $103.81
Previous CloseN/A
Volume113.34K
Average Volume (3M)1.15M
Market Cap
$2.95B
Enterprise Value$2.96B
Total Cash (Recent Filing)$180.97M
Total Debt (Recent Filing)$80.02M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Jul 31, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding55,328,667
10 Day Avg. Volume1,321,426
30 Day Avg. Volume1,149,731
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-36.74
Forecast
1Y Price Target
$81.43Price Target Upside48.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Clinical DataEarly PCa data shows impressive safety profile, with patients maintaining pre-surgery erectile function better and having much lower urinary incontinence compared to radical prostatectomy reference data.
EarningsRevenue exceeded expectations with a significant beat in both the US and international markets.
Bears Say
Macro-economic PressuresConcerns exist about macro-economic pressures, such as stressed hospital capital expenditure and tariffs, which could impact future utilization trends.
---
Ownership Overview
9.88% Insiders
37.16% Mutual Funds
0.22% Other Institutional Investors
37.11% Public Companies and
Individual Investors
PRCT FAQ
What was PROCEPT BioRobotics’s price range in the past 12 months?
PROCEPT BioRobotics lowest stock price was $47.04 and its highest was $103.81 in the past 12 months.
What is PROCEPT BioRobotics’s market cap?
PROCEPT BioRobotics’s market cap is $2.95B.
When is PROCEPT BioRobotics’s upcoming earnings report date?
PROCEPT BioRobotics’s upcoming earnings report date is Jul 31, 2025 which is in 83 days.
How were PROCEPT BioRobotics’s earnings last quarter?
PROCEPT BioRobotics released its earnings results on Apr 24, 2025. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.49 by $0.04.
Is PROCEPT BioRobotics overvalued?
According to Wall Street analysts PROCEPT BioRobotics’s price is currently Undervalued.
Does PROCEPT BioRobotics pay dividends?
PROCEPT BioRobotics does not currently pay dividends.
What is PROCEPT BioRobotics’s EPS estimate?
PROCEPT BioRobotics’s EPS estimate is -0.41.
How many shares outstanding does PROCEPT BioRobotics have?
PROCEPT BioRobotics has 55,328,667 shares outstanding.
What happened to PROCEPT BioRobotics’s price movement after its last earnings report?
PROCEPT BioRobotics reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.49. Following the earnings report the stock price went down -5.637%.
Which hedge fund is a major shareholder of PROCEPT BioRobotics?
Currently, no hedge funds are holding shares in PRCT
---
PROCEPT BioRobotics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.43 (48.57% Upside)
$81.43 (48.57% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 13.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.34%
12-Months-Change
Fundamentals
Return on Equity
-27.62%
Trailing 12-Months
Asset Growth
35.64%
Trailing 12-Months
Company Description
PROCEPT BioRobotics
PROCEPT BioRobotics (PRCT) is a medical technology company specializing in the development and commercialization of innovative robotic solutions for urology. The company's flagship product, the AquaBeam Robotic System, is designed to treat benign prostatic hyperplasia (BPH), a condition commonly known as an enlarged prostate. By integrating advanced imaging and robotics, the system provides surgeons with a minimally invasive option for prostate tissue removal, enhancing precision and reducing recovery times for patients.
---
PRCT Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call demonstrated strong revenue growth and strategic advancements, particularly in system sales and Medicare coverage, but was tempered by significant net losses and potential tariff impacts.Read More>---
PRCT Stock 12 Month Forecast
Average Price Target
$81.43
▲(48.57% Upside)
Technical Analysis
---